HAE
Haemonetics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 5
Sell signal 0
consensus rating "Strong Buy"
ample liquidity
High Gross Profit Margin
EPS Beats Expectation
Bullish Abandoned Baby
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About HAE
Haemonetics Corporation
A global healthcare company focused on the fields of blood and plasma component collection, the surgical suite, and hospital transfusion services
Healthcare Equipment and Supplies
Invalid Date
05/10/1991
New York Stock Exchange
3657
03-31
Common stock
125 Summer Street, 02110, Boston, Massachusetts 02110
--
Founded in 1971, Haemonetics Corporation is a global medical device company dedicated to providing customers with innovative blood management solutions — plasma source collectors, blood collection institutions and hospitals, with a strong brand advantage in medical device systems in the blood transfusion industry, providing customers with solutions while also providing information technology platforms and value-added services, its solutions help patients improve clinical outcomes, And improve the efficiency of the supply chain in the blood.
Company Financials
EPS
HAE has released its 2025 Q3 earnings. EPS was reported at 1.19, versus the expected 1.17, beating expectations. The chart below visualizes how HAE has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
HAE has released its 2025 Q3 earnings report, with revenue of 348.54M, reflecting a YoY change of 3.66%, and net profit of 37.49M, showing a YoY change of 20.02%. The Sankey diagram below clearly presents HAE’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available